Thursday, December 23, 2021 9:26:09 PM
Gaining the backing of clinical and scientific consensus experts is crucial to how the treatment is perceived in my world of actual medicine, not finance. The only thing NWBO has is the treatment and nothing about second guessing the way Linda Powers and Les Goldman are doing what they’re doing is going to make them change course; they know what they have and they’re working the strategy they’ve developed and they’re not going to change in mid stream. I believe they’ve worked this to a nub and I’m guessing we’re going to see some big names that will be important to our product be backing DCVax, even ones who’ve been detractors. The length of time in Peer Review is a clue to this (add COVID and we have quite the wait). And if this happens this is a slam dunk and having that backing against any noise about using historic controls becomes a non issue. This opens the doors wide open for trials for other indications and does the work up front instead of piecing it together each time against strong criticisms.
I’m quite sure of what I’m saying, I live in this space and know how these things can unfold. Experts who see the change of paradigm in front of them are not going to want to be the heal that made a bad call, they’ll want in on the chatter and take some kind of credit for it somehow some way. Trust me on this. And if you want to see something interesting look at Novocure’s price drop steadily from $227 to $84 in the past 6 months and insider sells, about the same time the Peer Review has been taking place. I don’t believe in coincidences. Ever get the feeling some troops are amassing at the border….?
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM